Epicutaneous Immunization with Type II Collagen Inhibits both Onset and Progression of Chronic Collagen-Induced Arthritis

Jessica Strid, Lee Aun Tan, Stephan Strobel et al. · 2007

Read Epicutaneous Immunization with Type II Collagen Inhibits both Onset and Progression of Chronic Collagen-Induced Arthritis by Jessica Strid, Lee Aun Tan, Stephan Strobel et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0000387.txt.

Introduction

Jessica Strid and colleagues tested an unusual route to calm arthritis, publishing in PLOS ONE in 2007. Instead of injecting a treatment, they applied type II collagen through the skin, a method called epicutaneous immunization. Collagen is a target of the immune attack in the arthritis model they used, where the body turns on its own joints.

The authors report that skin-based treatment with collagen held back both the start and the advance of chronic collagen-induced arthritis. Teaching the immune system to tolerate its own tissue, through the skin, could point toward gentler therapies for autoimmune disease. The study adds to work on needle-free ways to retrain immune responses.

Catalog record

CREATORJessica Strid, Lee Aun Tan, Stephan Strobel et al.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000387

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Epicutaneous Immunization with Type II Collagen Inhibits both Onset and Progression of Chronic Collagen-Induced Arthritis Authors: Jessica Strid, Lee Aun Tan, Stephan Strobel, Marco Londei, Robin Callard Published: 2007, PLOS ONE DOI: 10.1371/journal.pone.0000387 ABSTRACT Epicutaneous immunization is a potential non-invasive technique for antigen-specific immune-modulation. Topical application of protein antigens to barrier-disrupted skin induces potent antigen-specific immunity with a strong Th2-bias. In this study, we investigate whether the autoimmune inflammatory response of chronic collagen-induced arthritis (CCIA) in DBA/1-TCR-β Tg mice can be modified by epicutaneous immunization. We show that epicutaneous immunization with type II collagen (CII) inhibited development and progression of CCIA and, importantly, also ameliorated ongoing disease as indicated by clinical scores of disease severity, paw swelling and joints histology. Treated mice show reduced CII-driven T cell proliferation and IFN-γ production, as well as significantly lower levels of CII-specific IgG2a serum antibodies. In contrast, CII-driven IL-4 production and IgE antibody levels were increased consistent with skewing of the CII response from Th1 to Th2 in treated mice. IL-4 production in treated mice was inversely correlated with disease severity. Moreover, T cells from treated mice inhibited proliferation and IFN-γ production by T cells from CCIA mice, suggesting induction of regulatory T cells that actively inhibit effector responses in arthritic mice. The levels of CD4 + CD25 + T cells were however not increased following epicutaneous CII treatment. Together, these results suggest that epicutaneous immunization may be used as an immune-modulating procedure to actively re-programme pathogenic Th1 responses, and could have potential as a novel specific and simple treatment for chronic autoimmune inflammatory diseases such as rheumatoid arthritis. INTRODUCTION The route of antigen administration is a key factor in determining the nature of an immune response. The different responses obtained may enable alternative routes of antigen delivery to be used for generating therapeutic immune responses. In recent years, it has become clear that application of antigen onto bare skin induces potent systemic and mucosal immunity in an antigen-specific manner [1] – [3] . Several strategies to exploit the immune system of the skin for needle-free vaccine delivery are currently being developed [4] , [5] . These new strategies rely however on the use of strong non-specific adjuvants for induction of good immune responses, some of which are toxic and generally not acceptable for human immunization. We have recently shown that a natural adjuvant effect can be achieved by simply disrupting the stratum corneum of the epidermis prior to topical antigen application [1] . This activates the resident Langerhans cells and negates the need for coapplication of potentially noxious adjuvants. We have shown previously that epicutaneous immunization on barrier-disrupted skin induces potent and strongly Th2-biased immunity [1] , [6] . This is consistent with other studies showing that the epicutaneous microenvironment appears to naturally favour the induction of Th2 and generally anti-inflammatory responses [2] , [3] , [7] . Furthermore, we have shown that the Th2 response induced by epicutaneous immunization exerts a dominant effect over CFA-induced Th1 responses by interfering with the development of systemic antigen-specific Th1 responses and skewing established Th1 responses towards Th2 [6] . These observations suggest that this route of antigen delivery could be of potential therapeutic benefit in Th1-type autoimmune diseases such as rheumatoid arthritis (RA). RA is an autoimmune disease characterized by chronic inflammation, cyclic progressive evolution and ensuing destruction of cartilage and bone, leading to severe disability. The disease has a prevalence of 1%, making RA one of the most common chronic inflammatory diseases [8] , [9] . In spite of intense research, many of the principles behind the pathogenic mechanisms of RA still remain to be elucidated. However, cumulative evidence suggests that CD4 + T lymphocytes predominantly expressing a Th1 cytokine pattern drives the pathology [10] , [11] . Joint-specific autoantigens, such as type II collagen (CII) are thought to play a key role by instigating T cell mediated immune responses [12] with autoantibodies subsequently also being involved [8] . Several therapeutic strategies are available for RA and continuous improvement and refinement of these therapies have had a profound impact on progression of disease and quality of life for RA patients [13] . None of the currently used therapies are, however, disease- or antigen-specific and there is therefore a need for developing new disease-specific therapies which may benefit RA patients. DBA/1-TCR-β Tg mice develop a chronic relapsing polyarthritis with an incidence approaching 100% after immunization with CII in CFA. This model of chronic collagen-induced arthritis (CCIA) is dependent on CD4 + Th1 cells and shares key characteristics with human RA [12] . In this study, we use the CCIA model to investigate the potential of epicutaneous immunization to provide a means of modulating RA. We report, that epicutaneous immunization with CII protects against the development of CCIA and importantly is also effective in ameliorating disease when given after induction of CCIA. Epicutaneous immunization, whether prior or post induction of disease, inhibits pathogenic CII-driven Th1 responses and enhances anti-inflammatory Th2 responses. These results suggest, that this route of active autoantigen immunization may provide an alternative or complimentary therapeutic strategy for autoimmune diseases such as RA. RESULTS Topical application of protein antigen to skin from which the stratum corneum has been removed with adhesive tape gives rise to potent systemic immune responses [1] . Immunity initiated via such epicutaneous immunization is strongly Th2-biased with high levels of antigen-specific IgG1 and IgE and enhanced production of IL-4 but with little or no IgG2a and IFN-γ [1] . The Th2 responses obtained by this route are dominant over Th1 responses induced by antigen in CFA [6] , suggesting that epicutaneous immunization with an RA autoantigen could modulate disease in the CCIA model. To examine this possibility, DBA/1-TCR-β Tg mice were immunized epicutaneously with CII three weeks prior to induction of arthritis. Development of clinical disease was closely monitored for five weeks following arthritis induction ( Figure 1 ). A highly significant decrease in disease severity as well as a delay in the onset and an overall lower incidence of disease was observed in treated mice compared to sham treated CCIA diseased controls. The treated mice that did show disease developed a milder arthritis (p<0.0001) ( Figure 1A ) with reduced paw swelling (p<0.0001) ( Figure 1B ) and with fewer joints involved (p<0.0001) (data not shown). These results demonstrated a highly significant effect of epicutaneous immunization on both the incidence and evolution of clinical arthritis. DBA/1-TCR-β Tg mice were epicutaneously immunized with CII 3 weeks prior to induction of disease by injection of CII in CFA. Mice were evaluated and clinical score (A) and hind paw thickness (B) were assessed every second day. Data represents the mean+1 SEM (n = 9). The epicutaneous immunization had a highly significant effect on disease severity as analysed by two-way ANOVA. The entire in vivo experiment was repeated twice with very similar results. (•) = treated with epicutaneous CII, (▴) = sham-treated CCIA controls. HISTOLOGICAL FEATURES Hind paws were collected at the end of the experiment and joints evaluated histologically to determine whether the amelioration of disease in the treated mice correlated with reduced joint damage ( Figure 2A ). Sections of hind paws from healthy control animals showed open joint spaces

Read the complete text